• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Fate Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

    8/12/25 4:07:27 PM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $FATE alert in real time by email
    8-K
    FATE THERAPEUTICS INC NASDAQ false 0001434316 0001434316 2025-08-07 2025-08-07
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 OR 15(d)

    of The Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): August 7, 2025

     

     

    FATE THERAPEUTICS, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-36076   65-1311552
    (State or other jurisdiction
    of incorporation)
     

    (Commission

    File Number)

      (IRS Employer
    Identification No.)

     

    12278 Scripps Summit Dr.

    San Diego, CA

      92131
    (Address of principal executive office)   (Zip Code)

    Registrant’s Telephone Number, Including Area Code: 858 875-1800

    N/A

    (Former Name or Former Address, if Changed Since Last Report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading
    Symbol(s)

     

    Name of each exchange
    on which registered

    Common Stock, $0.001 par value   FATE   Nasdaq Global Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 2.02

    Results of Operations and Financial Condition.

    On August 12, 2025, Fate Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2025. A copy of the press release is attached as Exhibit 99.1.

    The information in this Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liability of that section, nor shall such information be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, regardless of the general incorporation language of such filing, except as shall be expressly set forth by specific reference in such filing.

     

    Item 2.05

    Costs Associated with Exit or Disposal Activities.

    On August 7, 2025, the Company’s Board of Directors approved a corporate restructuring to streamline operations, reduce operating expenses, and extend cash runway (the “Restructuring”). In connection with the Restructuring, the Company committed to a reduction in total workforce by approximately 12% (the “RIF”). Affected employees were informed on August 12, 2025.

    The Company expects the RIF to be completed during the third quarter of 2025, and estimates that it will incur charges of approximately $0.9 million to $1.2 million for severance and other employee termination-related costs during the third quarter of 2025. The Company may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the RIF. If the Company subsequently determines that it will incur additional significant costs associated with the RIF, it will amend this Current Report on Form 8-K to disclose such information.

    Forward-Looking Statements

    This Current Report on Form 8-K contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by such words as “expect,” “anticipate,” “intend,” “estimate,” and words of similar import and are based on current expectations that involve risks and uncertainties, such as the Company’s plans, objectives, expectations and intentions. All statements other than historical or current facts are forward-looking statements, including, without limitation, statements about the expected timing, magnitude and financial impact of the Restructuring and the RIF, anticipated extension of the Company’s cash runway, and the terms and conditions associated with the termination of employees. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially and adversely from those anticipated in the forward-looking statements. The statements in this Current Report on Form 8-K, including all forward-looking statements, speak only as of the date of this report.

     

    Item 9.01

    Financial Statements and Exhibits

    (d) Exhibits.

     

    Exhibit

    Number

      

    Description

    99.1    Press Release dated August 12, 2025
    104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: August 12, 2025   FATE THERAPEUTICS, INC.
        By:  

    /s/ Bahram Valamehr

          Bahram Valamehr, Ph.D., M.B.A.
          President and Chief Executive Officer
    Get the next $FATE alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FATE

    DatePrice TargetRatingAnalyst
    11/18/2024Underperform → Neutral
    BofA Securities
    6/17/2024$4.00 → $6.00Neutral → Overweight
    Piper Sandler
    3/27/2023$6.00Equal Weight
    Wells Fargo
    1/24/2023$115.00 → $7.00Buy → Neutral
    H.C. Wainwright
    1/6/2023$20.00 → $7.00Outperform → Market Perform
    BMO Capital Markets
    1/6/2023$71.00 → $12.00Overweight → Neutral
    Piper Sandler
    1/6/2023Outperform → Market Perform
    Cowen
    1/6/2023$107.00 → $5.30Buy → Hold
    Stifel
    More analyst ratings

    $FATE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Redmile Group, Llc sold $573,943 worth of shares (341,633 units at $1.68), bought $668,580 worth of shares (397,964 units at $1.68), disposed of $1,822,692 worth of shares (1,084,936 units at $1.68) and acquired $1,822,692 worth of shares (1,084,936 units at $1.68) (SEC Form 4)

    4 - FATE THERAPEUTICS INC (0001434316) (Issuer)

    12/26/24 9:00:15 PM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Redmile Group, Llc disposed of $6,157,976 worth of shares (1,655,370 units at $3.72), acquired $6,157,976 worth of shares (1,655,370 units at $3.72) and bought $166,024 worth of shares (44,630 units at $3.72) (SEC Form 4)

    4 - FATE THERAPEUTICS INC (0001434316) (Issuer)

    12/28/23 9:30:16 PM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FATE
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Fate Therapeutics Inc.

    SCHEDULE 13G/A - FATE THERAPEUTICS INC (0001434316) (Subject)

    8/14/25 11:30:17 AM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Fate Therapeutics Inc.

    10-Q - FATE THERAPEUTICS INC (0001434316) (Filer)

    8/12/25 4:09:49 PM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Fate Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - FATE THERAPEUTICS INC (0001434316) (Filer)

    8/12/25 4:07:27 PM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FATE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Tahl Cindy sold $9,573 worth of shares (9,037 units at $1.06), decreasing direct ownership by 2% to 397,670 units (SEC Form 4)

    4 - FATE THERAPEUTICS INC (0001434316) (Issuer)

    8/5/25 4:03:43 PM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and CEO Valamehr Bahram sold $15,396 worth of shares (14,466 units at $1.06), decreasing direct ownership by 4% to 334,898 units (SEC Form 4)

    4 - FATE THERAPEUTICS INC (0001434316) (Issuer)

    8/5/25 4:02:34 PM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    New insider Redco Ii Master Fund, L.P. claimed ownership of 8,977,624 shares (SEC Form 3)

    3 - FATE THERAPEUTICS INC (0001434316) (Issuer)

    7/3/25 4:03:21 PM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FATE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Fate Therapeutics upgraded by BofA Securities

    BofA Securities upgraded Fate Therapeutics from Underperform to Neutral

    11/18/24 3:46:41 PM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Fate Therapeutics upgraded by Piper Sandler with a new price target

    Piper Sandler upgraded Fate Therapeutics from Neutral to Overweight and set a new price target of $6.00 from $4.00 previously

    6/17/24 7:25:36 AM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Wells Fargo resumed coverage on Fate Therapeutics with a new price target

    Wells Fargo resumed coverage of Fate Therapeutics with a rating of Equal Weight and set a new price target of $6.00

    3/27/23 8:55:35 AM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FATE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment

    USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Aug. 14, 2025 /PRNewswire/ -- USA News Group News Commentary – Federal budget cuts have put pressure on cancer research efforts in the United States, but private investment is helping to fill the gap, with oncology ventures securing hundreds of millions in funding so far in 2025. The Senate's recent restoration of $15 million for the Pancreatic Cancer Research Program (PCARP) was a win, yet its earlier elimination underscored the fragility of public support. Against this backdrop, investors are zeroing in on companies with standout science, solid pipelines, and clear regulatory strategies, including Onc

    8/14/25 12:22:00 PM ET
    $FATE
    $INO
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical/Dental Instruments
    Biotechnology: Pharmaceutical Preparations

    Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates

    First patient treated with FT819 off-the-shelf CAR T-cell product candidate following fludarabine-free conditioning for severe lupus nephritis demonstrated durability of response with drug-free definition of remission in systemic lupus erythematosus (DORIS) at 12-month follow-up Held initial discussion with FDA under FT819 RMAT designation to seek feedback on registrational pathway in moderate-to-severe Systemic Lupus Erythematosus (SLE) and refractory Lupus Nephritis (LN) First extrarenal SLE patient treated with FT819 in the absence of conditioning, and as add-on to standard-of-care maintenance therapy, achieved Low Lupus Disease Activity State (LLDAS) at 3- and 6-month follow-up IND ap

    8/12/25 4:01:00 PM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

    SAN DIEGO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on August 4, 2025 the Company granted (i) non-qualified stock options to one newly-hired non-executive employee to purchase a total of 60,000 shares of the Company's common stock at an exercise price per share of $1.06, which was the closing price per share of the Company's common stock as reported by NASDAQ on August 4, 2025, the options grant date, and (ii) restricted stock u

    8/5/25 4:01:00 PM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FATE
    Financials

    Live finance-specific insights

    View All

    Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

    First Lupus Patient Treated with FT819 CAR T-cell Product Candidate in Phase 1 Autoimmunity Study; Future Clinical Development of FT819 to Focus Exclusively on Autoimmune Disease Enrollment Initiated with FT522 CAR NK Cell Product Candidate in Conditioning-free Treatment Arm of Phase 1 B Cell Lymphoma Study First Patient Treated with FT825 / ONO-8250 CAR T-cell Product Candidate in Phase 1 Solid Tumor Study $391 Million in Cash, Cash Equivalents, and Investments SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPS

    5/9/24 4:01:00 PM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2024 Financial Results and Operational Updates

    SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the "Company" or "Fate Therapeutics") (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, will host a conference call and live audio webcast on Thursday, May 9, 2024 at 5:00 PM ET to report its first quarter 2024 financial results and highlight operational updates, including a review of its FT819 and FT522 programs for autoimmune diseases being featured on the same day at the American Society of Gene and Cell Therapy 27th Annual Meeting. In order

    5/6/24 8:00:00 AM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

    CIRM Grant Awarded to Support Phase 1 Autoimmunity Study of FT819 CD19-targeted CAR T-cell Program for Systemic Lupus Erythematosus; Study Start-up Ongoing at Multiple Clinical Sites First Patient Treated in Phase 1 Study of FT522 ADR-armed, CD19-targeted CAR NK Cell Program; Dose Escalation Designed to Assess 3-dose Treatment Schedule with and without Chemotherapy Conditioning Phase 1 Study Initiated of FT825 / ONO-8250 CAR T-cell Program for Solid Tumors; Incorporates Seven Synthetic Controls including Novel Cancer-specific CAR Targeting HER2 $316 Million in Cash, Cash Equivalents, and Investments SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FA

    2/26/24 4:01:00 PM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FATE
    Leadership Updates

    Live Leadership Updates

    View All

    Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors

    SAN DIEGO, May 30, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived off-the-shelf cellular immunotherapies to patients, today announced the appointment of Matthew Abernethy, M.B.A., to its Board of Directors effective as of May 29, 2025. Mr. Abernethy brings to the Company over 15 years' experience in corporate finance and investor relations in the biotech and medical device industry. In addition, the Company announced that Timothy P. Coughlin stepped down from the Board of Directors, effective concurrently with Mr. Abernethy's appointment. "Mr. Aberne

    5/30/25 4:30:14 PM ET
    $FATE
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Fate Therapeutics Announces Leadership Transition

    Bob Valamehr, Ph.D. MBA, To Become President and CEO January 1, 2025 Scott Wolchko To Retire as President and CEO after 10 years of Leadership in Pioneering iPSC-derived Cellular Immunotherapies SAN DIEGO, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE) ("Fate Therapeutics" or the "Company"), a clinical-stage biopharmaceutical company dedicated to bringing first-in-class induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that Scott Wolchko, the Company's President and CEO, will retire effective December 31, 2024. Fate's current President of Research and Development (R&D), Bob Vala

    11/29/24 1:05:00 PM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Fate Therapeutics Appoints Neely Mozaffarian, MD, PhD, FACR, to its Board of Directors

    SAN DIEGO, July 31, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced the appointment of Neely Mozaffarian, MD, PhD, FACR, to its Board of Directors effective immediately. Dr. Mozaffarian brings to the Company medical and scientific leadership in the field of immunology and autoimmunity, with over 20 years of research and industry experience in the discovery, development, and commercialization of novel small and large molecule therapeutics. "Dr. Moza

    7/31/24 8:00:00 AM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FATE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Fate Therapeutics Inc.

    SC 13G/A - FATE THERAPEUTICS INC (0001434316) (Subject)

    11/14/24 7:50:18 PM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Fate Therapeutics Inc.

    SC 13G/A - FATE THERAPEUTICS INC (0001434316) (Subject)

    10/25/24 9:37:07 PM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D/A filed by Fate Therapeutics Inc. (Amendment)

    SC 13D/A - FATE THERAPEUTICS INC (0001434316) (Subject)

    3/25/24 5:15:23 PM ET
    $FATE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care